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Key points: 
The seroprevalence of anti-SARS-CoV-2 antibodies of police officers was comparable to that 
reported in the general population. The level of serum antibody titres, in particular that of anti-
spike antibodies, correlate well with neutralization capacity. Low antibody titres acquired from 

























Background: Protests and police fieldwork provides a high exposure environment for SARS-CoV-2 
infections. In this cross-sectional analysis, we investigated the seroprevalence among a police 
cohort, and sociodemographic, work and health-related factors associated with seropositivity.  
Methods: Study participants were invited for serological testing of SARS-CoV-2 and to complete 
online questionnaires. Serum neutralization titres towards the wild-type SARS-CoV-2 spike protein 
(expressing D614G) and the alpha and beta variants were measured in seropositive study 
participants.  
Results: 978 police personnel representing 35% of the entire staff participated from February to 
March 2021. The seroprevalence was 12.9%. It varied by geographic region within the canton; 
ranged from 9% to 13.5% in three regions, including the city; and was 22% in Bernese Seeland/Jura 
with higher odds for seropositivity (OR 2.38, 95% CI 1.28–4.44, P=0.006). Job roles with mainly office 
activity were associated with a lower risk of seropositivity (0.33, 0.14–0.77, P=0.010). Most 
seropositive employees (67.5%) reported having had COVID-19 three months or longer prior to 
serological testing. Selfreported compliance with mask wearing during working hours was 100%; 
45% of all seropositive versus 5% of all seronegative participants (P<0.001) reported having had 
contact with a proven COVID-19 cas  living in the same household prior to serological testing. The 
level of serum antibody titres correlated with neutralization capacity. Antibodies derived from 
natural SARS-CoV-2 infection effectively neutralized the SARS-CoV-2 spike protein, but were less 
effective against the alpha and beta variants.  
Conclusions: The seroprevalence of anti-SARS-CoV-2 antibodies of police officers was comparable 
to that reported in the general population, suggesting that the personal protective equipment of 
the police is effective, and that household contacts are the leading transmission venues. The level 
of serum antibody titres, in particular that of anti-spike antibodies, correlated well with 
neutralization capacity. Low antibody titres acquired from natural infection were not effective 






















Serological surveys that detect antibodies against SARS-CoV-2 antigens provide information on the 
prevalence in groups that might be more exposed to the virus or have had higher rates of infection 
[1]. They help researchers to quantify the protective effect of mitigation efforts. Although the 
majority of workers exposed to proven SARS-CoV-2 are employed in healthcare sectors, other 
occupations have been associated with an increased risk for coronavirus disease 2019 (COVID-19). 
Police officers are one such commonly exposed group. In contrast to healthcare workers, this special 
population has contact with a frequently changing and unpredictable population [2]. Physical 
distancing is often not possible. Unlike healthcare workers, police officers have no information 
pertaining to potential infectious diseases of the involved parties. Previous studies have shown that 
droplet and aerosol emission of contagious organisms occurs during speech [3-5] and increases with 
voice loudness [6]. These data underscore the risk of exposure to SARS-CoV-2 that may occur in 
fieldwork. This notion is even more important considering that the COVID-19 pandemic has ignited 
social unrest, including domestic violence and a surge in COVID-19 negations and anti-masking and 
anti-vaccine protests worldwide [7-12]. It is reasonable to hypothesize that police officers, in 
particular those working in the field, are a high-exposure population. 
To assess the risk for COVID-19 in this group, we are studying a cohort consisting of individuals 
employed by the Cantonal Police Bern in Switzerland [13]. The aim of this cross-sectional analysis 
was to determine the seroprevalence of SARS-CoV-2 antibodies in employees of the cantonal police 
and to investigate individual and work-related factors associated with seropositivity. We also 
measured antibody titres of naturally acquired SARS-CoV-2 infection and correlated the results with 
the neutralizing capacity of the antibodies towards the “wild-type” SARS-CoV-2 spike (S) protein 
























The first wave: The first case of COVID-19 was confirmed in Switzerland on February 25, 2020. On 
March 16, 2020, schools and most businesses were closed nationwide. On March 20, 2020, all 
gatherings of more than five people in public spaces were banned. The measures were gradually 
removed between late April and June 2020. On July 6, 2020, the Federal Council ordered mandatory 
face masks on public transport for all individuals 12 years of age or older. 
The second wave: New measures were imposed in October 2020 as cases surged again.  
Mask wearing: Wearing face masks for employees of the Cantonal Police Bern was recommended on 
August 28, 2020, and made mandatory during working hours on October 13, 2020. The types of 
mask provided by the police to their employees included surgical masks (type IIR) and police cloth 
masks certified by a material sciences and technology institute [14]. 
Viral strains: The viral strain consisting of the mutation D614G in the S protein (Nextstrain clade 
20A and its descendants) was the dominating circulating variant in 2020 in Switzerland [15]. The 
alpha variant B.1.1.7 became the common variant in Switzerland starting mid-⁠ February 2021 
[16]. 
Study population 
The police force of the canton of Bern employs over 2,800 individuals, located across 58 police 
stations in cities and rural areas. The cantonal police have four regions of activity in bilingual 
(German and French) areas, including the capital of the country (Bern city). The departments are 
subcategorized as regional, criminal, prevention and environment, and others. Rules and regulations 





















Recruitment period, questionnaires, and blood sampling 
Study enrolment opened on December 21, 2020. Study participants who fulfilled the inclusion 
criteria (employees of the Cantonal Police Bern, aged 18-65 years) were asked to fill out two online 
questionnaires prior to being given appointments for blood sampling from February 9 to March 9, 
2021. For every study participant, we collected coded, self-reported data on age and gender, 
education, job role within the police department, percentage employment, geographic region for 
work and living areas, and underlying health conditions. In addition, self-reported data on personal 
protective equipment use and hygiene precautions, symptoms consistent with COVID-19, contact 
with presumed or confirmed cases, quarantine and nasopharyngeal test results were obtained. The 
vast majority of nasopharyngeal swab tests included PCR technology, because rapid antigen tests 
became available through health professionals in Switzerland in November 2020 and for use by the 
general population in April 2021 (i.e., after recruiting and blood sampling). Answers to questions 
were provided prior to reporting the antibody test results.  
After testing for the presence of antibodies, we contacted seropositive individuals again for an 
additional questionnaire on their subjective views about where the transmission possibly occurred. 
Antibody tests 
SARS-CoV-2 antibodies to the nucleocapsid protein (NCP) and spike (S) protein were measured by 
using two commercially available immunoassays: anti-SARS-CoV-2 and anti-SARS-CoV-2 S (Roche 
Diagnostics, Rotkreuz, Switzerland). Both immunoassays detect antibodies independent of isotype, 
detecting predominantly IgG antibodies, as well as IgA and IgM antibodies. The anti‑SARS‑CoV‑2 
assay is based on antibody detection to a recombinant SARS-CoV-2 NCP, whereas the anti-SARS-CoV-
2 S uses a recombinant receptor binding domain antigen, which is found on subunit 1 of the spike 
protein. The NCP immunoassay reports a cut-off index (COI; signal of sample/cut-off) in which values 
≥ 1.00 are considered positive, whereas the S immunoassay is a semi-quantitative method and 




















positive. The tests were performed on the Roche cobas 8000 e801 analyser according to the 
manufacturer’s instructions (Roche Diagnostics, Rotkreuz, Switzerland).  
Test strategy for analysis 
The cross-sectional baseline investigation was performed in a non-vaccinated population, because 
samples were obtained prior to initiating a vaccine programme for the employees of the police. First, 
all study participants were tested for the presence of anti-NCP antibodies [17]. The rationale for this 
testing strategy included the high specificity and sensitivity of the anti-NCP 
electrochemiluminescence immunoassay (ECLIA) test evaluated in our laboratory [18, 19]. Second, 
all anti-NCP seropositive samples were then also tested for anti-S antibodies. The rationale for 
testing anti-S antibodies in NCP-seropositive individuals relied on the intended neutralization assays 
and correlation statistics between anti-NCP and anti-S antibody titres. Among seronegative samples, 
only those from individuals who reported having had a positive test result from a nasopharyngeal 
swab in the online questionnaire were tested for anti-S antibodies (supplemental fig A).  
Serum neutralization assays 
The assays were performed as previously described [20]. In brief, 20,000 Vero E6 cells were seeded 
in a 96-well plate format. The following ay, heat-inactivated sera were two-fold serial diluted and 
mixed with 200 plaque forming units of the indicated isogenic SARS-CoV-2 virus, which were 
generated, rescued, and propagated [20]. After one hour of pre-incubation at room temperature, 
the mixture was added to Vero E6 cells and incubated at 37°C. After 4 days, cells were fixed with 4% 
formalin and stained with crystal violet to analyse the reciprocal dilution at which SARS-CoV-2 was 
neutralized. We used isogenic SARS-CoV-2 viruses harbouring either the D614G spike, the full-






















Seropositive individuals included those with a positive result and seronegative individuals those with 
a negative result in the anti-NCP antibody assay. The sample size calculation conducted prior to the 
study yielded a 95% confidence interval width of 4%, assuming a true seroprevalence of 12% to 
13% and inclusion of 1,000 study participants [13]. To describe characteristics of the study cohort, 
we used mean ± standard deviation (SD) or median with interquartile range for summarizing 
continuous variables, as appropriate. Comparisons were made by using the Student t test or Mann-
Whitney test, respectively. Categorical data were shown as numbers with percentages and 
compared by using Fisher's exact test for binary variables or the chi-squared test for more than two 
categories, unless indicated as having been tested for a non-parametric trend, following the 
approach of Cuzick [21]. To investigate whether the outcome (seropositivity) was associated with a 
set of exposures, we used logistic regression on the entire cohort and on the sub-cohort of exposed 
subjects. We addressed the question of how well specific symptoms separate seropositive 
participants from those who tested negative by using random forests with 500 iterations. We 
calculated the odds ratio with the confidence interval, sensitivity, specificity, and C statistic (= area 
under the receiver operating characteristic curve) of the symptom with the highest importance. In 
seropositive patients, we visualized the correlation between antibody concentration (anti-NCP and 
anti-S) with maximal dilution of the neutralization tests and calculated Spearman correlation 
coefficients. We also investigated whether anti-NCP and anti-S antibody titres were equally 
associated with neutralization serum titres of the three different virus variants by using multilevel 
mixed effects ordered logistic regression (i.e., the level of serum neutralization titres as ordered 
categories). We calculated separate analyses, including both anti-NCP and anti-S antibodies as 
covariates into the model as continuous variables or dichotomized by the median, respectively.  All 





















Patient Consent Statement 
All participants gave written informed consent prior to enrolment in the PoliCOV-19 study. 




A total of 989 individuals were enrolled in the study until March 9, 2021. Five individuals withdrew 
consent, and six missed the appointment for blood sampling. Hence, 978 employees of the Cantonal 
Police Bern were included in the final analysis, reflecting 35% of the entire staff. The proportion was 
representative in view of geographic distribution and job roles (data not shown). At the time of 
blood sampling, only two individuals were vaccinated with an mRNA vaccine (supplemental fig A). 
Both of them were anti-NCP seronegative. 
Seroprevalence 
A total of 852 (87.1%) individuals were seronegative and 126 (12.9%) were seropositive at their anti-
NCP antibody assay (table 1). Except for two individuals (1.6%), all anti-NCP seropositive samples 
were also positive for anti-S IgG (supplemental fig A). 
Seroprevalence varied by geographic region within the canton; it ranged from 9% to 13.5% in three 
regions, including the city, and was 22% in Bernese Seeland and Bernese Jura (fig 1 and table 1).  
Individuals who worked in the regions Bernese Seeland and Bernese Jura had significantly higher 
odds of having anti-SARS-CoV-2 antibodies than did those working in other regions (OR 2.38 [95%CI 
1.28 – 4.44] in supplemental table A). 
High public exposure (e.g., regional police with a high proportion of fieldwork activity) was 
associated with seropositivity (table 1). Conversely, roles with mainly office activity (i.e., 
interdepartmental) were associated with a lower risk of seropositivity (odds ratio 0.33, 95% 




















In 85 (67.5%) of 126 seropositive individuals, the time interval between COVID-19 and blood 
sampling was 3 months or longer. Twenty-four (19%) study participants did not know when their 
infection occurred. There was no difference in anti-NCP and anti-S antibody titre results when we 
compared ECLIA values with the time intervals of 1 month, 2 months, 3 months, and longer 
(supplemental fig B). 
Ninety-nine individuals reported having had a prior positive nasopharyngeal swab test result; 94 of 
them (95%) were seropositive for anti-NCP and 96 (97%) for anti-S antibodies. Only three (3%) of the 
positive tested individuals showed no seroconversion (supplemental table C). Three hundred thirty-
six individuals reported never having had COVID-19 symptoms and that they were not tested; 329 
(98%) of them were seronegative for anti-NCP antibodies.  
Symptoms 
Symptoms consistent with COVID-19 were significantly more frequent in the seropositive than in the 
seronegative group (table 2). Among reported symptoms, “new loss of smell or taste” was the best 
discriminator (supplemental fig C). This symptom was associated with an odds ratio of 52.4 (95% 
confidence interval 30.9 to 89.0, P<0.001) for seropositivity, a sensitivity of 64% (55% to 72%), a 
specificity of 97% (95% to 98%), and an area under the receiver operating characteristic curve of 80% 
(76% to 85%). 
Personal protective equipment use, absenteeism, quarantine, transmission venues 
Reported compliance with wearing masks during working hours was 100%, irrespective of the 
presence of anti-SARS-CoV-2 antibodies (supplemental table D).  
Two hundred forty-four individuals (25%) missed work (including home office) or were absent from 
the police academy because of suspected or confirmed COVID-19 or because of quarantine. Two 
hundred twenty-four (23%) individuals were placed in quarantine because of exposure to a person 
with proven or suspected COVID-19, and 65 (29%) were subsequently seropositive. These 65 




















employees who were placed in quarantine (and who remained seronegative) reflected 19% of all 
seronegative study participants (P<0.001). 
The investigation on possible transmission venues specifically differentiated between contacts 
during working hours and household, and between “presumed” and “proven” (i.e., confirmed with a 
nasopharyngeal swab test) COVID-19 contact. Fifty-seven (45%) of 126 seropositive individuals 
reported of having had contact with a proven COVID-19 case living in the same household. 
Conversely, 5% of all seronegative individuals reported the same type of exposure. This proportion 
difference was statistically significant (P<0.001). This was not the case when reported contacts 
during working hours or contacts with presumed (but not proven) cases were analysed (table 3). 
Subjective assessment of study participants on the source of transmission 
Among seropositive individuals, 75 (60%) felt “certain” or “likely certain” about the source of 
transmission (supplemental table E). Sixty-one (48%) reported that the contact had occurred during 
a private activity or within the same household.  
Neutralization capacity and correlation with ECLIA results 
The required dilution titres for neutralization showed a considerable distribution among the study 
participants (fig 2). The median dilution titre was significantly higher in assays that used D614G than 
in those that used B.1.1.7 (P<0.001) and B.1.351 (P<0.001). Similarly, the median dilution titre was 
significantly higher in assays that used B.1.1.7 than in those that used B.1.351 (P<0.001). Antibody 
titres of anti-NCP- and anti-S antibodies correlated with the dilution titres showing the highest 
coefficient with dilution of D614G and the lowest coefficient with dilution of B.1.351 (beta), with 
P<0.001 in all pairs (supplemental table F). Antibodies from seropositive individuals demonstrated 
neutralization activity against D614G up to a dilution of 1:320 (supplemental fig D). The dilutions 
were lower for B.1.1.7 (1:40 for anti-S antibodies and 1:80 for anti-NCP antibodies) and for B.1.351 
variants (1:20) (supplemental figs E and F), indicating a poorer neutralization capacity towards virus 




















We then searched for cut-off values of anti-NCP antibodies and anti-S antibodies in ECLIA results 
that demonstrated neutralization in the assay. We explored antibody titres as both continuous and 
binary variables in separate statistical models to mathematically predict the level of neutralization. 
For the latter, we used the median values of all results (i.e., >37.5 COI for anti-NCP antibodies and 
>65 U/mL for anti-S antibodies) and hence, assembled four combination categories (fig 3). Similar to 
the overall results of neutralization assays, the neutralization capacity of serum against alpha and 
beta variants was poorer than it was against D614G, even with serum demonstrating both >37.5 
U/mL COI anti-NCP antibodies and >65 U/mL anti-S antibodies. In the model with both continuous 
and ordered categories, odds ratios of anti-S antibodies for the level of neutralization were higher 
than those of anti-NCP antibodies. While the antibody titres above the cut-off level of >37.5 U/mL 
were associated with about a three-fold increase in level of neutralization, anti-S1 antibody titres 
above >65 U/mL were associated with about a six-fold increase (supplemental table G).  
 
Discussion 
This cross-sectional population serological survey among the police cohort demonstrated a pre-
vaccinated anti-SARS-CoV-2 antibody seroprevalence of 13%. Few studies have investigated 
seroprevalence in police officers, which include those performed in New York, NY, USA [22] and 
Mazowieckie Province, Poland [23] as well as two further studies with low sample sizes [24, 25].  
However, our study did not demonstrate a higher seroprevalence than observed in the general 
population of the canton of Bern (i.e., 14%), which was investigated in another study using a 
different serological test [26, 27]. The results indicate that the use of personal protective equipment 
is effective in mitigating the risk of COVID-19. This is in line with the reported high compliance with 
mask wearing in our study population. However, within the police cohort, the odds for seropositivity 
were higher for fieldwork activity with high exposure to the general population than they were for 




















difference observed for contacts in the private environment and when comparing geographic 
districts is in line with the findings of others [22, 28, 29].  
During the first wave of the pandemic in Switzerland, testing individuals with few or no symptoms 
was not recommended, and symptoms consistent with COVID-19 were presumed to be COVID-19 
related. In the police cohort, nearly 50% of individuals experienced sore throat, congestion, or a 
runny nose, although only 5% to 7% were seropositive. In our analysis, new loss of taste or smell was 
associated with high specificity in predicting seropositivity, underscoring the importance of testing, 
considering that numerous other viruses can cause a variety of respiratory symptoms. Following 
proven infection with SARS-CoV-2, most individuals in our cohort developed detectable serum 
antibodies towards both the NCP and the S protein. To assess ex-vivo humoral immunity within our 
cohort, we investigated the magnitude of neutralizing antibodies towards SARS-CoV-2 strains that 
did and did not circulate within the population prior to blood sampling.  
Considering that the sampling occurred from February 9 to March 9, the vast majority of our 
cohort was exposed to the virus strain harbouring the D614G S protein [15]. Exposure to the alpha 
and beta variant was unlikely in our cohort [16], in particular when considering he reported time 
points of infection (supplemental fig B). In line with these observations, naturally acquired 
antibodies demonstrated good neutralization activity against D614G but performed suboptimal 
against the alpha variant and poorly against the beta variant. We observed a correlation between 
the ECLIA titres and the highest dilutions still demonstrating neutralization. Our results imply that 
the interaction between the spike protein and anti-S antibodies may play an important role in the 
neutralization tests. They point towards the importance of high anti-S antibody titres, and hence, 
the value of the vaccine achieving this goal. Although the variants show mutations mainly in the 
spike protein, variations in the capsule have gained less attention. In line with our results, the 
contribution to virus neutralization of anti-NCP antibodies is less known [30]. 
Our study has limitations. The study population may contain a response bias in comparison to the 




















February 2021 and we used anti-NCP antibodies as the main marker of seropositivity. We cannot 
exclude that in certain individuals with COVID-19 in 2020 anti-NCP antibodies have waned below 
the detection level and that the true seroprevalence is underestimated. In our experience, the 
antibody titres remain at a detectable level for a prolonged period, and the proportion of 
agreement with reported nasopharyngeal swab test results was high. Therefore, and in 
consideration of a 95% confidence interval width of 4%, we are convinced that the seroprevalence 
proportion found in our analysis is a valid result. We categorized our analysis only in anti-NCP 
seropositive and seronegative individuals and did not correct for sensitivity and specificity. Two 
individuals with a history of a positive nasopharyngeal tests had positive anti-S without anti-NCP 
antibodies, and our test strategy did not include dual testing for all study participants (supplemental 
fig. A). It is therefore possible that we included very few false positive or false negative serum 
samples in our analysis. Given the high sensitivity and specificity of the antibody tests [19, 31], we 
do not believe that excluding these few samples would have changed the overall results. The 
results from nasopharyngeal swab tests were obtained via online questionnaire, and the 
questionnaires on the subjective view of transmission routes may consist of a recall bias. 
Moreover, the directionality of transmission remains unknown, and identifying index and contact 
cases is subject to testing and reporting bias.  The choice of median cut-off values of antibody titres 
in association with serum neutralization assays is arbitrary and does not reflect clinical 
circumstances. More sophisticated methods to find an optimal cut-off such as receiver operating 
characteristic curves would have required a fixed and already established cut-off for serum 
neutralization titre. We chose a conservative cut-off, supported by the sensitivity analysis with 
antibody titres as a continuous independent variable.  
In conclusion, our COVID-19 cross-sectional survey among police officers demonstrated a 
seroprevalence of 13% in a pre-vaccinated cohort. This proportion is similar to that reported in the 
general population. The high compliance with mask wearing and the low proportion of 




















imply that personal protective equipment is effective. The high proportion of seropositive 
individuals who have had contact with a proven COVID-19 case in the same household suggests that 
most known transmissions within our police cohort did not occur within working hours. The level of 
serum antibody titres, in particular that of anti-S antibodies, correlated well with the neutralization 
capacity. Antibodies derived from natural SARS-CoV-2 antibodies effectively neutralized viral 
strains that – from an epidemiological point of view – most likely caused the infection. However, 
at low titres (i.e., below the median of the study population), antibodies were not effective against 
the alpha and beta variants. These findings support vaccine programmes for both seropositive and 






























1. Ong DSY, Fragkou PC, Schweitzer VA, Chemaly RF, Moschopoulos CD, Skevaki C. How to interpret and use COVID-
19 serology and immunology tests. Clin Microbiol Infect 2021; 27(7): 981-6. 
2. Baker MG, Peckham TK, Seixas NS. Estimating the burden of United States workers exposed to infection or 
disease: A key factor in containing risk of COVID-19 infection. PLoS One 2020; 15(4): e0232452. 
3. Loudon RG, Roberts RM. Singing and the dissemination of tuberculosis. Am Rev Respir Dis 1968; 98(2): 297-300. 
4. Asadi S, Wexler AS, Cappa CD, Barreda S, Bouvier NM, Ristenpart WD. Effect of voicing and articulation manner 
on aerosol particle emission during human speech. PLoS One 2020; 15(1): e0227699. 
5. Jones RM, Brosseau LM. Aerosol transmission of infectious disease. J Occup Environ Med 2015; 57(5): 501-8. 
6. Asadi S, Wexler AS, Cappa CD, Barreda S, Bouvier NM, Ristenpart WD. Aerosol emission and superemission 
during human speech increase with voice loudness. Sci Rep 2019; 9(1): 2348. 
7. Bradbury-Jones C, Isham L. The pandemic paradox: The consequences of COVID-19 on domestic violence. J Clin 
Nurs 2020. 
8. Boserup B, McKenney M, Elkbuli A. Alarming trends in US domestic violence during the COVID-19 pandemic. Am J 
Emerg Med 2020. 
9. Mazza M, Marano G, Lai C, Janiri L, Sani G. Danger in danger: Interpersonal violence during COVID-19 quarantine. 
Psychiatry Res 2020; 289: 113046. 
10. Roesch E, Amin A, Gupta J, García-Moreno C. Violence against women during covid-19 pandemic restrictions. Bmj 
2020; 369: m1712. 
11. Taylor L. Covid-19: Vaccine corruption allegations spark protests across Brazil. Bmj 2021; 374: n1724. 
12. Fasehun LO. Reviewing COVID-19 Modelling amidst Recent United States Protests. Ann Glob Health 2020; 86(1): 
76. 
13. Sendi P. Police Officer COVID-19 Seroprevalence Survey in the Canton of Bern, Switzerland. Available at: 
https://clinicaltrials.gov/ct2/show/NCT04643444.  
14. EMPA. Projekt 'ReMask'. 2021. 
15. Hodcroft EB, Zuber M, Nadeau S, et al. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. 
Nature 2021. 
16. Health FOoP. COVID- ⁠ 19 Switzerland Information on the current situation. Available at: 
https://www.covid19.admin.ch/en/epidemiologic/virus-variants/d/overview. Accessed 2021. 
17. Burbelo PD, Riedo FX, Morishima C, et al. Sensitivity in Detection of Antibodies to Nucleocapsid and Spike 
Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019. J Infect 
Dis 2020; 222(2): 206-13. 
18. Riester E, Krieter B, Findeisen P, et al. Performance of an automated anti-SARS-CoV-2 immunoassay in 
prepandemic cohorts. medRxiv 2020: 2020.08.07.20169987. 
19. Riester E, Majchrzak M, Mühlbacher A, et al. Multicentre Performance Evaluation of the Elecsys Anti-SARS-CoV-2 
Immunoassay as an Aid in Determining Previous Exposure to SARS-CoV-2. Infect Dis Ther 2021: 1-17. 
20. Ulrich L, Halwe NJ, Taddeo A, et al. Enhanced fitness of SARS-CoV-2 variant of concern B.1.1.7, but not B.1.351, in 
animal models. bioRxiv 2021: 2021.06.28.450190. 
21. Cuzick J. A Wilcoxon-type test for trend. Stat Med 1985; 4(1): 87-90. 
22. Sami S, Akinbami LJ, Petersen LR, et al. Prevalence of SARS-CoV-2 Antibodies in First Responders and Public 
Safety Personnel, New York City, New York, USA, May-July 2020. Emerg Infect Dis 2021; 27(3): 796-804. 
23. Gujski M, Jankowski M, Pinkas J, et al. Prevalence of Current and Past SARS-CoV-2 Infections among Police 
Employees in Poland, June-July 2020. J Clin Med 2020; 9(10). 
24. Halatoko WA, Konu YR, Gbeasor-Komlanvi FA, et al. Prevalence of SARS-CoV-2 among high-risk populations in 
Lomé (Togo) in 2020. PLoS One 2020; 15(11): e0242124. 
25. Chughtai OR, Batool H, Khan MD, Chughtai AS. Frequency of COVID-19 IgG Antibodies among Special Police 
Squad Lahore, Pakistan. J Coll Physicians Surg Pak 2020; 30(7): 735-9. 
26. Bern Uo. Only 14% of the Bernese population have antibodies against coronavirus. Available at: 
https://www.unibe.ch/news/media_news/media_relations_e/media_releases/2021/media_releases_2021/only_
14_of_the_bernese_population_have_antibodies_against_coronavirus/index_eng.html.  
27. West EA, Anker D, Amati R, et al. Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 
seroprevalence and seroepidemiologic studies in Switzerland. Int J Public Health 2020; 65(9): 1529-48. 
28. Fung HF, Martinez L, Alarid-Escudero F, et al. The household secondary attack rate of SARS-CoV-2: A rapid review. 
Clin Infect Dis 2020. 
29. Madewell ZJ, Yang Y, Longini IM, Jr., Halloran ME, Dean NE. Household Transmission of SARS-CoV-2: A Systematic 
Review and Meta-analysis. JAMA Netw Open 2020; 3(12): e2031756. 
30. Brochot E, Demey B, Touzé A, et al. Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 
Inpatients and Asymptomatic Individuals. Front Microbiol 2020; 11: 584251. 
31. Riester E, Findeisen P, Hegel JK, et al. Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S 




































The study was funded in part by the Cantonal Police of Bern, Bern, Switzerland. This funding party 
had no influence in the study design, interpretation of results, and generation of the manuscript. The 
Institute for Infectious Diseases of the University of Bern and the Interregional Blood Transfusion 
Swiss Red Cross, Bern, Switzerland, supported the study by providing working hours of their 
employees specifically for this study and by providing material and consumables at cost or for free. 






















Potential Conflicts of Interest 
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf 
and declare no conflict of interest.  
Roche (manufacturer of the ECLIA tests) had no influence in any part of this study. The test was 
commercially purchased by the investigators. The lead author (PS) affirms that the manuscript is an 
honest, accurate, and transparent account of the study being reported and that no important 
aspects of the study have been omitted. 
 
Acknowledgment 
We thank Dr. Volker Thiel (Institute of Virology and Immunology and Department of Infectious 
Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland) for providing the 
viral strains. We thank the numerous volunteers and the study team members from the affiliated 
and other institutions for their help in conducting the study, including Medbase Zweisimmen, 
Medicentre Moutier, and numerous others. We thank all the employees of the Cantonal Police Bern 
for participating. We are grateful to Annetta Redmann, CTU, University of Bern, for her databank 


























Figure 1: Map of the canton of Bern in Switzerland. The different colours indicate the corresponding 
geographic regions. The overall seroprevalence was 12.9% (i.e., 126 of 978 samples displayed anti-
nucleocapsid protein antibodies). Responses of 963 study participants were available; 15 
seronegative individuals did not provide their geographic working district. 
 
Figure 2: Results of neutralization assays performed with serum of study participants (n=126) and 
isogenic SARS-CoV-2 viruses harbouring either the D614G spike, the full-length B117 spike (alpha 
variant), or the full-length B.1.351 spike (beta variant). Each dot represents the results of a study 
participant. Each sample was tested against all three strains. The red dashed line reflects the limit of 
detection. The numbers on the y-axis indicate the highest dilution of serum demonstrating 
neutralization activity. The boxplots display the distribution of data between the first quartile, 
median, and third quartile. A Wilcoxon rank sum and signed rank test was performed to compare the 
groups. ****: P<0.0001. wt-S = wild-type spike. 
 
Figure 3: Results of neutralization assays categorized according to selected cut-off ECLIA values of 
anti-nucleocapsid protein (NCP) antibodies (cut-off index ≤37.5 and >37.5) and anti-spike (S) 
antibodies (≤65 U/mL and >65 U/mL). The combination of these values result in four groups. The 
boxplots display the distribution of data between the first quartile, median, and third quartile of 
serum neutralization titres of each group. The numbers on the y-axis indicate the highest serum 


































Age – years; mean (SD) 880 40 (8.9) 39 (9.0) 41 (8.8) 0.12 
Gender – no. (%) 973    0.67 
Female  270 (28%) 37 (29%) 233 (27%)  
Male  703 (72%) 89 (71%) 614 (72%)  
Comorbidity – no. (%) or 
mean (SD) 
     
Body mass index kg/m
2
  975 26 (3.5) 26 (3.3) 26 (3.5) 0.46 
Diabetes mellitus 972 13 (1.3%) 3 (2.4%) 10 (1.2%) 0.23 
Arterial hypertension 973 78 (8.0%) 10 (7.9%) 68 (8.0%) 1.00 
Cardiovascular disease 971 17 (1.7%) 3 (2.4%) 14 (1.6%) 0.47 
Lung disease 973 27 (2.8%) 2 (1.6%) 25 (2.9%) 0.56 
Immunosuppression 971 12 (1.2%) 2 (1.6%) 10 (1.2%) 0.66 
Other disease 973 101 (10%) 10 (7.9%) 91 (11%) 0.43 
No comorbidity 978 761 (78%) 100 (79%) 661 (78%) 0.73 
Education – no. (%) 974    0.16 
Police academy  795 (81%) 114 (90%) 681 (80%)  
Security assistant school  53 (5.4%) 4 (3.2%) 49 (5.8%)  
University degree  63 (6.4%) 3 (2.4%) 60 (7.0%)  
Merchant  32 (3.3%) 2 (1.6%) 30 (3.5%)  
Craftsman  18 (1.8%) 2 (1.6%) 16 (1.9%)  
Other  13 (1.3%) 1 (0.79%) 12 (1.4%)  
No. of years working for the 
police – mean (SD) 
915 11 [7.0, 19] 11 [7.0, 20] 11 [6.5, 19] 0.75 
Working region within the 
canton – no. (%) 
963    0.006 
Seeland, Bernese Jura  170 (17%) 37 (29%) 133 (16%)  
Mittelland, Emmental, 
Oberaargau 
 193 (20%) 22 (17%) 171 (20%)  
Bernese Oberland  132 (13%) 14 (11%) 118 (14%)  
Region Bern  229 (23%) 31 (25%) 198 (23%)  
Bern City  239 (24%) 22 (17%) 217 (25%)  
Department – no. (%) 973    0.017 
Regional police  649 (66%) 90 (71%) 559 (66%)  
Criminal police  118 (12%) 20 (16%) 98 (12%)  
Traffic, environment, 
prevention 
 72 (7.4%) 10 (7.9%) 62 (7.3%)  
Interdepartmental  120 (12%) 6 (4.8%) 114 (13%)  
Other  14 (1.4%) 0 (0.00%) 14 (1.6%)  
Main activity – no. (%) 939    0.038 
Fieldwork  559 (57%) 84 (67%) 475 (56%)  
Office work  380 (39%) 39 (31%) 341 (40%)  
% of working hours in the 
field, mean (SD)  
952 46 (27) 51 (25) 45 (27) 0.024 
% of working hours in the 
office, mean (SD) 
976 50 [30, 80] 40 [30, 70] 50 [30, 80] 0.012 
1
All except two individuals with anti-nucleocapsid protein (NCP) antibodies also displayed anti-spike antibodies 
(see supplemental fig A). 
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Table 2: Clinical symptoms reported by study participants during the COVID-19 pandemic.  
 










Fever 954 130 (13%) 41 (33%) 89 (11%) <0.001 
Chills 949 137 (14%) 41 (33%) 96 (11%) <0.001 
Fatigue 959 547 (56%) 102 (81%) 445 (53%) <0.001 
Muscle or body aches 947 142 (15%) 47 (37%) 95 (11%) <0.001 
Sore throat 963 406 (42%) 56 (44%) 350 (41%) 0.56 
Congestion or runny nose 959 479 (49%) 73 (58%) 406 (48%) 0.045 
New loss of taste or smell 948 107 (11%) 80 (63%) 27 (3.2%) <0.001 
Shortness of breath or 
difficulty breathing 
948 135 (14%) 42 (33%) 93 (11%) <0.001 
Chest pain 947 129 (13%) 33 (26%) 96 (11%) <0.001 
Cough or other respiratory 
symptoms 
937 84 (8.6%) 20 (16%) 64 (7.6%) 0.004 
Headache 955 263 (27%) 75 (60%) 188 (22%) <0.001 
Nausea or vomiting 945 65 (6.7%) 13 (10%) 52 (6.1%) 0.09 
Abdominal pain 941 71 (7.3%) 8 (6.3%) 63 (7.4%) 0.85 
Diarrhoea 945 133 (14%) 26 (21%) 107 (13%) 0.018 
 
*Values are numbers (percentages). 
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Table 3: Comparison of seropositive (i.e., seroconversion) and seronegative (i.e., no seroconversion) 
individuals after having had contact with a proven or presumed COVID-19 case. 
 
Reasons for being in 
quarantine 










Contact with a person living in 
the same household who had 
COVID-19  
(proven with a test) 
978 102 (10%) 57 (45%) 45 (5.3%) <0.001 
Contact with a person living in 
the same household who had 
presumable COVID-19  
(not proven with a test) 
977 105 (11%) 20 (16%) 85 (10%) 0.06 
Contact with a person at work 
who had COVID-19  
(proven with a test) 
977 364 (37%) 43 (34%) 321 (38%) 0.49 
Contact with a person at work 
who had presumable COVID-
19  
(not proven with a test) 
976 192 (20%) 22 (17%) 170 (20%) 0.55 
 
*Values are numbers (percentages). 
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